Azathioprine with prednisone for polymyositis. A controlled, clinical trial

T. W. Bunch, J. W. Worthington, J. J. Combs, D. M. Ilstrup, Andrew G Engel

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

A controlled, prospective, double-blind, therapeutic trial of azathioprine was conducted in the initial therapy of polymyositis. Sixteen patients received 60 mg prednisone per day plus either azathioprine (2 mg/kg of body weight per day) or placebo for a period of 3 mth. Creatine phosphokinase (CPK) levels fell to normal slightly sooner in the placebo group, but not significantly so. The azathioprine group did not become significantly stronger (P = 0.58) and did not manifest significantly greater improvement of histopathologic features of muscle (P = 0.80) than the placebo group. Initial CPK elevations were significantly related to the degree of muscle inflammation (P = 0.037), but this was not the case at 3 mth (P > 0.05). Normalization of the CPK could not be equated with disease control. Type II fiber atrophy, attributed to steroid therapy, was more marked in women than in men (P < 0.03).

Original languageEnglish (US)
Pages (from-to)365-369
Number of pages5
JournalAnnals of Internal Medicine
Volume92
Issue number3
StatePublished - 1980

Fingerprint

Polymyositis
Controlled Clinical Trials
Azathioprine
Creatine Kinase
Prednisone
Placebos
Muscles
Atrophy
Therapeutics
Steroids
Body Weight
Inflammation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bunch, T. W., Worthington, J. W., Combs, J. J., Ilstrup, D. M., & Engel, A. G. (1980). Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Annals of Internal Medicine, 92(3), 365-369.

Azathioprine with prednisone for polymyositis. A controlled, clinical trial. / Bunch, T. W.; Worthington, J. W.; Combs, J. J.; Ilstrup, D. M.; Engel, Andrew G.

In: Annals of Internal Medicine, Vol. 92, No. 3, 1980, p. 365-369.

Research output: Contribution to journalArticle

Bunch, TW, Worthington, JW, Combs, JJ, Ilstrup, DM & Engel, AG 1980, 'Azathioprine with prednisone for polymyositis. A controlled, clinical trial', Annals of Internal Medicine, vol. 92, no. 3, pp. 365-369.
Bunch, T. W. ; Worthington, J. W. ; Combs, J. J. ; Ilstrup, D. M. ; Engel, Andrew G. / Azathioprine with prednisone for polymyositis. A controlled, clinical trial. In: Annals of Internal Medicine. 1980 ; Vol. 92, No. 3. pp. 365-369.
@article{4ad87308756c4c47848a0b6c41783f24,
title = "Azathioprine with prednisone for polymyositis. A controlled, clinical trial",
abstract = "A controlled, prospective, double-blind, therapeutic trial of azathioprine was conducted in the initial therapy of polymyositis. Sixteen patients received 60 mg prednisone per day plus either azathioprine (2 mg/kg of body weight per day) or placebo for a period of 3 mth. Creatine phosphokinase (CPK) levels fell to normal slightly sooner in the placebo group, but not significantly so. The azathioprine group did not become significantly stronger (P = 0.58) and did not manifest significantly greater improvement of histopathologic features of muscle (P = 0.80) than the placebo group. Initial CPK elevations were significantly related to the degree of muscle inflammation (P = 0.037), but this was not the case at 3 mth (P > 0.05). Normalization of the CPK could not be equated with disease control. Type II fiber atrophy, attributed to steroid therapy, was more marked in women than in men (P < 0.03).",
author = "Bunch, {T. W.} and Worthington, {J. W.} and Combs, {J. J.} and Ilstrup, {D. M.} and Engel, {Andrew G}",
year = "1980",
language = "English (US)",
volume = "92",
pages = "365--369",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Azathioprine with prednisone for polymyositis. A controlled, clinical trial

AU - Bunch, T. W.

AU - Worthington, J. W.

AU - Combs, J. J.

AU - Ilstrup, D. M.

AU - Engel, Andrew G

PY - 1980

Y1 - 1980

N2 - A controlled, prospective, double-blind, therapeutic trial of azathioprine was conducted in the initial therapy of polymyositis. Sixteen patients received 60 mg prednisone per day plus either azathioprine (2 mg/kg of body weight per day) or placebo for a period of 3 mth. Creatine phosphokinase (CPK) levels fell to normal slightly sooner in the placebo group, but not significantly so. The azathioprine group did not become significantly stronger (P = 0.58) and did not manifest significantly greater improvement of histopathologic features of muscle (P = 0.80) than the placebo group. Initial CPK elevations were significantly related to the degree of muscle inflammation (P = 0.037), but this was not the case at 3 mth (P > 0.05). Normalization of the CPK could not be equated with disease control. Type II fiber atrophy, attributed to steroid therapy, was more marked in women than in men (P < 0.03).

AB - A controlled, prospective, double-blind, therapeutic trial of azathioprine was conducted in the initial therapy of polymyositis. Sixteen patients received 60 mg prednisone per day plus either azathioprine (2 mg/kg of body weight per day) or placebo for a period of 3 mth. Creatine phosphokinase (CPK) levels fell to normal slightly sooner in the placebo group, but not significantly so. The azathioprine group did not become significantly stronger (P = 0.58) and did not manifest significantly greater improvement of histopathologic features of muscle (P = 0.80) than the placebo group. Initial CPK elevations were significantly related to the degree of muscle inflammation (P = 0.037), but this was not the case at 3 mth (P > 0.05). Normalization of the CPK could not be equated with disease control. Type II fiber atrophy, attributed to steroid therapy, was more marked in women than in men (P < 0.03).

UR - http://www.scopus.com/inward/record.url?scp=0018907021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018907021&partnerID=8YFLogxK

M3 - Article

C2 - 6986827

AN - SCOPUS:0018907021

VL - 92

SP - 365

EP - 369

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -